drugset / Trial / NCT05751252
Sub-therapeutic GnRH- Antagonist Treatment to Rectify LH Pulsatility in Lean Women With PCOS.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The clinical study using a sub-therapeutic dose of a GnRH antagonist to reduce overactive LH pulsatility in women with PCOS. With the intervention and lowered LH action we anticipate to decrease androgen levels in women with PCOS. The aim to show for the first time that low-dose GnRH-antagonists can lower LH pulsatility by 20-30% and decrease androgen levels without blunting the hypothalamic-pituitary-gonadal axis and thereby the reproductive functions.
Timeline
- Start
- 2024-04-17
- Primary completion
- 2025-02-09
- Completion
- 2025-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ganirelix | Protein / enzyme biologic | 0.025 mg | Subcutaneous |
| Subject | Ganirelix | Protein / enzyme biologic | 0.0625 mg | Subcutaneous |